This past year has been an exciting one for JAMA Oncology and its editors. We have had the pleasure of receiving a substantial number of submissions and reviewing a diverse and interesting array of topics. Diversity in the oncology workforce and disparities in health equity were common topics. Articles ranged from data on lack of access to cancer screening for some populations, to the inability to access health technology, to the role of zip code in cancer care. We continued to receive reports about the COVID-19 pandemic in cancer, including studies that explore the efficacy of specific vaccines on the more aggressive variants of the virus and the role of booster immunizations in enhancing immune responses in patients. We have reported results from several large phase 3 randomized clinical trials affecting standard of care as well as exciting and promising results from smaller phase 1 and 2 studies with outstanding correlative science. We hope that you enjoyed reading these articles as much as we enjoyed choosing the best manuscripts for publication. We thank the many authors, reviewers, and readers for the significant contributions made to the journal this past year. The JAMA Oncology editorial board, editors, and I are honored to have the opportunity to serve the oncology community by offering original, innovative, and timely scientific content that has a direct effect on researchers, clinicians, and the patients we serve. The impact factor of 33.01 placed JAMA Oncology as one of the highest-ranking oncology journals.
Choosing manuscripts for the journal was rewarding, but challenging. We received a total of 2712 submissions this past year, including 1603 Original Investigations, 289 Brief Reports, 234 Research Letters, 117 Viewpoints, and 85 Reviews and Special Communications. In 2022, we published 382 total manuscripts, including 102 Original Investigations, 33 Viewpoints, and 15 Reviews and Special Communications. I would like to thank these authors for choosing JAMA Oncology. The quality of their published manuscripts is reflected in the more than 4 million readers who have viewed or downloaded JAMA Oncology articles.
In 2022, the acceptance rates were 14% for overall submissions and 8% for Original Investigations and Brief Reports, 16% for Research Letters, 25% for Review articles, 29% for Viewpoints, and 12% for Clinical Challenges. JAMA Oncology is widely indexed in many databases, including PubMed/MEDLINE and Web of Science. More detailed statistics about the journal’s content, reach, and performance are displayed in the Table.1-9
We are also very grateful to our global consortium of peer reviewers who contributed to the journal this year. We are pleased to acknowledge their contributions to JAMA Oncology by publishing the names of the more than 800 experts who completed a manuscript review in 2022.10 This group of laboratory, clinical, quantitative, and statistical scientists rapidly provided comprehensive reviews of the submitted manuscripts. The median time for peer review was 13 days, and median time from the receipt of a manuscript to the first editorial decision with peer review was 43 days in 2022. The ability to rapidly review and return a decision on our submissions ensures that important findings are available to the oncology community as quickly as possible. We would not be able to provide this service without our expert peer reviewers and their commitment to providing prompt and high-quality reviews for the journal. We thank you!
We also thank our readers. The journal’s table of contents of newly published material is sent by email each week to more than 86 000 recipients. If you currently do not receive the JAMA Oncology table of contents by email, you can sign up at http://www.jamaoncology.com. We are pleased to continue offering provocative and timely research for scientists, clinicians, and trainees in the field of oncology worldwide. We encourage readers to stay involved with the journal by submitting Letters to the Editor and sending us recommendations for new topics that you would like to see covered in future issues. Your suggestions make this interdisciplinary oncology journal dynamic and current.
Finally, I would like to thank George W. Sledge Jr, MD, for his outstanding work as our Associate Editor for Editorials, Viewpoints, and Commentaries since the inception of the journal. George’s wisdom and wit kept many of our editorial meetings lively. Good luck on the new job, George—you are already missed. I also welcome 2 new editors, Reshma Jagsi, MD, DPhil, who will step into the shoes of Associate Editor for Viewpoints, Editorials, and Commentaries, and Narjust Florez, MD, who is the Associate Editor for Diversity, Equity, and Inclusion. Their strong voices will surely assist in keeping JAMA Oncology relevant and unique.
We have truly enjoyed being involved in JAMA Oncology’s continued success this year, and we look forward to the year ahead. We could not have done it without you. We invite all of our readers to follow us on Twitter @JAMAOnc or friend us on Facebook along with a combined social media community of over 98 000 people. We will keep you up to date on the most important discoveries influencing cancer care.
Back to top
Article Information
Corresponding Author: Mary L. (Nora) Disis, MD, University of Washington, 850 Republican St, Brotman 221, Box 358050, Seattle, WA 98195 (ndisis@uw.edu).
Published Online: March 23, 2023. doi:10.1001/jamaoncol.2023.0235
Conflict of Interest Disclosures: Dr Disis reported personal fees from JAMA Oncology and grants from Bavarian Nordic, Veanna, Precigen, Aston Sci, and Pfizer; in addition, Dr Disis had a patent for University of Washington with royalties paid.
References
Momozawa Y, Sasai R, Usui Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2022;8(6):871-878. doi:10.1001/jamaoncol.2022.0476PubMedGoogle ScholarCrossref
Shore ND, Renzulli J, Fleshner NE, et al. Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial. JAMA Oncol. 2022;8(8):1128-1136. doi:10.1001/jamaoncol.2022.1641PubMedGoogle ScholarCrossref
Ricciuti B, Wang X, Alessi JV, et al. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 2022;8(8):1160-1168. doi:10.1001/jamaoncol.2022.1981PubMedGoogle ScholarCrossref
Lawrence WR, McGee-Avila JK, Vo JB, et al. Trends in cancer mortality among Black individuals in the US from 1999 to 2019. JAMA Oncol. 2022;8(8):1184-1189. doi:10.1001/jamaoncol.2022.1472PubMedGoogle ScholarCrossref
Clarke MA, Devesa SS, Hammer A, Wentzensen N. Racial and ethnic differences in hysterectomy-corrected uterine corpus cancer mortality by stage and histologic subtype. JAMA Oncol. 2022;8(6):895-903. doi:10.1001/jamaoncol.2022.0009PubMedGoogle ScholarCrossref
Liau LM, Ashkan K, Brem S, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2023;9(1):112-121. doi:10.1001/jamaoncol.2022.5370PubMedGoogle ScholarCrossref
Fernandez AI, Liu M, Bellizzi A, et al. Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol. 2022;8(4):1-4. doi:10.1001/jamaoncol.2021.7239PubMedGoogle ScholarCrossref
Obeid M, Suffiotti M, Pellaton C, et al. Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients. JAMA Oncol. 2022;8(5):e220446. doi:10.1001/jamaoncol.2022.0446PubMedGoogle ScholarCrossref
Anscher MS, Arora S, Weinstock C, et al. Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US Food and Drug Administration database. JAMA Oncol. 2022;8(2):232-240. doi:10.1001/jamaoncol.2021.6439PubMedGoogle ScholarCrossref
JAMA Oncology peer reviewers in 2022. JAMA Oncol. Published online March 23, 2023. doi:10.1001/jamaoncol.2023.0220Google ScholarCrossref